Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

April 13, 2027

Study Completion Date

April 13, 2027

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Inebilizumab

Inebilizumab administered intravenously (IV) over a total of 28 weeks.

Trial Locations (18)

11000

RECRUITING

Clinic for Neurology and Psychiatry for Children and Youth, Belgrade

17176

RECRUITING

Karolinska Universitetssjukhuset Solna, Stockholm

92354

RECRUITING

Loma Linda University Children's Hospital - PIN, Loma Linda

94275

RECRUITING

Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre

92037-1337

RECRUITING

UCSD Altman Clinical and Translational Research Institute Building, La Jolla

02115

RECRUITING

Massachusetts General Hospital, Boston

C1245AAM

RECRUITING

Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Parque Patricios

40050-410

RECRUITING

Hospital Santa Izabel-Rua Floriano Peixoto 300, Salvador

90610-000

RECRUITING

Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre/RS

01228-000

RECRUITING

CPQuali Pesquisa Clínica Sao Paulo, São Paulo

05403-000

RECRUITING

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

M5G 1X8

RECRUITING

Hospital For Sick Children, Toronto

3015 GD

RECRUITING

Erasmus MC Sophia Children's Hospital-Wytemaweg 80, Rotterdam

80-952

RECRUITING

Uniwersyteckie Centrum Kliniczne w Gdansku - Smoluchowskiego 17, Gdansk

08950

RECRUITING

Hospital Sant Joan de Deu - PIN, Espluges de Llobregat

SE1 7EH

RECRUITING

Evelina London Children's Hospital, London

WC1N 3JH

RECRUITING

Great Ormond Street Hospital - PPDS, London

B4 6NH

RECRUITING

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY